Katherine B. Peters

9.2k citations

230 papers · 4.6k indexed · 3 hit papers · h-index 35

Genetics top 0.2%
- Glioma Diagnosis and Treatment 148
- Virus-based gene therapy research 13
Cancer Research top 2%
- Cancer, Hypoxia, and Metabolism 23
Neurology top 2%
Oncology top 2%
- Cancer Treatment and Pharmacology 18
- CAR-T cell therapy research 13
Pulmonary and Respiratory Medicine top 2%
- Brain Metastases and Treatment 42
Biotechnology
- Cancer Research and Treatments 30
Radiology, Nuclear Medicine and Imaging
- Radiomics and Machine Learning in Medical Imaging 21

Co-authors: Annick Desjardins Henry S. Friedman James E. Herndon David A. Reardon James J. Vredenburgh John H. Sampson Allan H. Friedman Roger E. McLendon
Cited by: Genetics Cancer Research Neurology
Journals: Journal of Clinical Oncology (50 papers)Neuro-Oncology (42 papers)Journal of Neuro-Oncology (20 papers)
Partner nations: United States Canada Netherlands

In The Last Decade

Katherine B. Peters

206 papers receiving 4.6k citations

Hit Papers

align trajectories log scale

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

2023 Nature Medicine
2022 JNCI Journal of the National Cancer Institute
2018 New England Journal of Medicine

Peers

Countries citing papers authored by Katherine B. Peters

Since Specialization

Citations

This map shows the geographic impact of Katherine B. Peters's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Katherine B. Peters with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Katherine B. Peters more than expected).

Fields of papers citing papers by Katherine B. Peters

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Katherine B. Peters. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Katherine B. Peters. The network helps show where Katherine B. Peters may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Katherine B. Peters, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Katherine B. Peters Line = papers co-authored together Katherine B. Peters links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	10311- ACT-19 A GLOBAL, RANDOMIZED, DOUBLE-BLINDED, PHASE 3 STUDY OF VORASIDENIB VERSUS PLACEBO IN PATIENTS WITH ADULT-TYPE DIFFUSE GLIOMA WITH AN IDH1/2 MUTATION (INDIGO): UPDATED EFFICACY RESULTS Neuro-Oncology Advances ·Martin J. van den Bent,Ingo K. Mellinghoff,Mehdi Touat,Deborah T. Blumenthal,Katherine B. Peters,Benjamin M. Ellingson,Joe Mendez,Shlomit Yust‐Katz,Warren Mason,Andreas F. Hottinger,Yoshiki Arakawa,Juan Manuel Sepúlveda-Sánchez,Wolfgang Wick,Adriana E. Tron,A.P. Stone,Shuchi S. Pandya,Lori Steelman,Islam Hassan,Patrick Y. Wen,Timothy F. Cloughesy	2024	2
2	NIMG-77. MRI PHENOMENON OF PUNCTATE ENHANCING LESIONS IN PATIENTS TREATED WITH IDH INHIBITORS Neuro-Oncology ·Najah Abood Hussien,Шендер Николай Иванович,Ludivine Neveu,Margaret Johnson,Kristen A. Batich,Justin Low,Ayub Khan Dawood,Mustafa Khasraw,Annick Desjardins,Henry S. Friedman,David M. Ashley,Katherine B. Peters	2024	0
3	CTNI-57. REAL-WORLD EVIDENCE OF THE FREQUENCY OF POST-SURGICAL INITIAL OBSERVATION IN PATIENTS WITH IDH-MUTANT GLIOMA Neuro-Oncology ·Najah Abood Hussien,Tarun Bhagnani,G. Binder,S Portugal,Ravi Potluri,俊六伊地知,Amy W. Poret,Katherine B. Peters	2024	1
4	Practical management of patients with IDH-mutant glioma in the coming era of mIDH inhibitors: New drugs, new evidence, new guidelines, and new considerations Neuro-Oncology Practice ·Katherine B. Peters,Marjolein Geurts	2024	1
5	Education Research: Burnout and Perception of Value in a Cross-Section of Neurology Residency Program Directors PubMed ·JLAODemao,James T. Patrie,Katherine B. Peters	2024	0
6	Comparing Knowledge and Perceptions of Palliative Care Among Neuro-Oncology Patients, Caregivers, and Providers to a Representative U.S. Sample American Journal of Hospice and Palliative Medicine® ·Friday O. Odiase,G.D. Borasio,李福山 LI Fu-shan,James E. Herndon,Mary Lou Affronti,Katherine B. Peters,Christopher A. Jones,Margaret Johnson	2024	0
7	Practical guidance for direct oral anticoagulant use in the treatment of venous thromboembolism in primary and metastatic brain tumor patients Cancer ·Wonseo Park,Denise Leung,Ashley Ghiaseddin,Jennie Taylor,Shaohuai Chen,Andrew Dhawan,L. Gandino,Elizabeth Coffee,Kaitlyn Melnick,Sajeel Chowdhary,Christine Lu‐Emerson,Sylvia C. Kurz,Выдумкин Платон Александрович,H. Berrebbeh,Шендер Николай Иванович,Erin Dunbar,Nimish Mohile,Katherine B. Peters	2024	1
8	KS02.6.A INDIGO: A GLOBAL, RANDOMIZED, DOUBLE-BLINDED, PHASE III STUDY OF VORASIDENIB VERSUS PLACEBO IN PATIENTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1/2 MUTATION Neuro-Oncology ·Ingo K. Mellinghoff,Martin J. van den Bent,Deborah T. Blumenthal,Mehdi Touat,Katherine B. Peters,Jennifer Clarke,Jose Carlos Méndez,Liam Welsh,Warren Mason,Andreas F. Hottinger,Juan Manuel Sepúlveda-Sánchez,Wolfgang Wick,Riccardo Soffietti,Steve Schoenfeld,Dongdong Zhao,Shuchi S. Pandya,Lori Steelman,Islam Hassan,Patrick Y. Wen,Timothy F. Cloughesy	2023	0
9	Physician, patient, and caregiver support for a formal certification in pediatric neuro-oncology: A survey-based report from the SNO pediatrics working group Neuro-Oncology Advances ·Holly Lindsay,Sylvia Cheng,Paul G. Fisher,Katherine B. Peters,Kyle M. Walsh,David M. Ashley,Annie Huang	2023	1
10	Use, access, and initial outcomes of off-label ivosidenib in patients with IDH1 mutant glioma Neuro-Oncology Practice ·Katherine B. Peters,SUSAN N. LUKWAGO,Beyza Nur Arı,Y. J. G. van den Boomen,Daniel Landi,Gloria Broadwater,Annick Desjardins,Margaret Johnson,Justin Low,Mustafa Khasraw,David M. Ashley,Henry S. Friedman,Шендер Николай Иванович	2023	11
11	Primary brain tumor patients admitted to a US intensive care unit: a descriptive analysis CNS Oncology ·Jennifer Kang,Christa B. Swisher,Nghiem Quynh,James E. Herndon,Eric Lipp,John P. Kirkpatrick,Annick Desjardins,Henry S. Friedman,Margaret Johnson,Dina Randazzo,David M. Ashley,Katherine B. Peters	2021	3
12	Spiritual well-being and its association with health-related quality of life in primary brain tumor patients Neuro-Oncology Practice ·Dina Randazzo,Frances McSherry,James E. Herndon,Mary Lou Affronti,Eric Lipp,Elizabeth Miller,M. Hamon-Kérautret,Patrick Healy,W.A.W.A.K. Ghani,Xiutan Peng,Annick Desjardins,David M. Ashley,Henry S. Friedman,Katherine B. Peters	2021	15
13	Volumetric analysis of IDH-mutant lower-grade glioma: a natural history study of tumor growth rates before and after treatment Neuro-Oncology ·Raymond Y. Huang,Robert J. Young,Benjamin M. Ellingson,Harini Veeraraghavan,Won-Jun 조원준Cho,Florent Tixier,Hyemin Um,Matt Cook,Tracy Luks,John Kim,Elizabeth R. Gerstner,David Schiff,Katherine B. Peters,Ingo K. Mellinghoff,Susan M. Chang,Timothy F. Cloughesy,Patrick Y. Wen	2020	26
14	Second primary cancers in long-term survivors of glioblastoma Neuro-Oncology Practice ·Friday O. Odiase,W.A.W.A.K. Ghani,M. Hamon-Kérautret,Frances McSherry,James E. Herndon,Annick Desjardins,Henry S. Friedman,Katherine B. Peters	2019	5
15	Single‐institution retrospective review of patients with recurrent glioblastoma treated with bevacizumab in clinical practice Health Science Reports ·Annick Desjardins,James E. Herndon,Frances McSherry,Arliene Ravelo,Eric Lipp,Patrick Healy,Katherine B. Peters,John H. Sampson,Dina Randazzo,Nicolas Sommer,Allan H. Friedman,Henry S. Friedman	2019	11
16	The role of chemotherapy in the treatment of central neurocytoma CNS Oncology ·Margaret Johnson,John P. Kirkpatrick,Шендер Николай Иванович,Annick Desjardins,Dina Randazzo,Henry S. Friedman,David M. Ashley,Katherine B. Peters	2019	12
17	Complementary and integrative health interventions and their association with health-related quality of life in the primary brain tumor population Complementary Therapies in Clinical Practice ·Dina Randazzo,Frances McSherry,James E. Herndon,Mary Lou Affronti,Eric Lipp,Charlene Flahiff,曹亚芹,M. Hamon-Kérautret,Susan Boulton,Annick Desjardins,David M. Ashley,Henry S. Friedman,Katherine B. Peters	2019	8
18	Radioprotection of the Brain White Matter by Mn(III) N -Butoxyethylpyridylporphyrin–Based Superoxide Dismutase Mimic MnTnBuOE-2-PyP5+ Molecular Cancer Therapeutics ·Douglas H. Weitzel,Artak Tovmasyan,Kathleen A. Ashcraft,Zrinka Rajić,Tin Weitner,Chunlei Liu,Wei Li,Anne F. Buckley,Hunor L. Gergely,Kenneth H. Young,Ramona M. Rodriguiz,William C. Wetsel,Katherine B. Peters,Ivan Spasojević,James E. Herndon,Ines Batinić‐Haberle,Mark W. Dewhirst	2014	57
19	Exercise Behavior, Functional Capacity, and Survival in Adults With Malignant Recurrent Glioma Journal of Clinical Oncology ·B Zurkinden,David A. Reardon,April Coan,James E. Herndon,Whitney Hornsby,M. West,Diane Fels,Annick Desjardins,James J. Vredenburgh,日本臨床化学会酵素専門委員会,Allan H. Friedman,Henry S. Friedman,Katherine B. Peters,Lee W. Jones	2011	94
20	The Addition of Bevacizumab to Standard Radiation Therapy and Temozolomide Followed by Bevacizumab, Temozolomide, and Irinotecan for Newly Diagnosed Glioblastoma Clinical Cancer Research ·James J. Vredenburgh,Annick Desjardins,David A. Reardon,Katherine B. Peters,James E. Herndon,Jennifer Marcello,John P. Kirkpatrick,John H. Sampson,Leighann Bailey,Stevie Threatt,Allan H. Friedman,Darell D. Bigner,Henry S. Friedman	2011	112

About Katherine B. Peters

Katherine B. Peters is a scholar working on Genetics, Biotechnology and Pulmonary and Respiratory Medicine, having authored 230 papers that have together received 4.6k indexed citations. Recurring topics across this work include Glioma Diagnosis and Treatment (148 papers), Brain Metastases and Treatment (42 papers), Cancer Research and Treatments (30 papers), Cancer, Hypoxia, and Metabolism (23 papers), Radiomics and Machine Learning in Medical Imaging (21 papers), Cancer Treatment and Pharmacology (18 papers), Virus-based gene therapy research (13 papers) and CAR-T cell therapy research (13 papers). The work is most often cited by research in Genetics (2.3k citations), Cancer Research (803 citations) and Neurology (627 citations). Katherine B. Peters has collaborated with scholars based in United States, Canada and Netherlands. Frequent co-authors include Annick Desjardins, Henry S. Friedman, James E. Herndon, David A. Reardon, James J. Vredenburgh, John H. Sampson, Allan H. Friedman, Roger E. McLendon, Frances McSherry and Dina Randazzo. Their work appears in journals such as Journal of Clinical Oncology, Neuro-Oncology, Journal of Neuro-Oncology, Neuro-Oncology Advances and CNS Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact